icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
Real-world effectiveness and cost per SVR of
Sofosbuvir/Velpatasvir in chronic hepatitis C treatment

 
 
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
 
Peter Buggisch1, Petar Atanasov2, Karsten Wursthorn1, Albrecht Stoehr1, Jorg Petersen1 1Asklepios Klinik St. Georg, IFI Institut fur Interdisziplinare Medizin, Hamburg, Germany 2Amaris, London, United Kingdom

0501171

EASL:No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 12 Weeks in DAA-Experienced Patients: an Integrated Resistance Analysis of the POLARIS-1 and POLARIS-4 Studies- (04/26/17)
 
AASLD:A Randomized, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study- (11/15/16)
 
AASLD:A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Nave Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study- (11/15/16)
 
AASLD:Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients With Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study- (11/15/16)
 
AASLD:Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study- (11/30/15)
 
AASLD:Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection- (11/30/15) published

0501172

0501173

0501174

0501175